Literature DB >> 11840073

Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.

Fahad S Al-Dossary1, Lydia T Ong, Armando G Correa, Jeffrey R Starke.   

Abstract

BACKGROUND: Recommended treatment of childhood tuberculosis is 6 months in duration with at least 3 drugs. We studied a regimen requiring as few as 58 doses, given entirely by directly observed therapy (DOT), under program conditions.
METHODS: An observational trial was conducted to determine the effectiveness of a completely DOT 6-month regimen for pulmonary, pleural and lymph node tuberculosis in children with the use of 2 weeks of daily isoniazid, rifampin and pyrazinamide therapy; then 6 weeks of twice weekly isoniazid, rifampin and pyrazinamide therapy; followed by 16 weeks of twice weekly isoniazid and rifampin. All therapy was given by workers from the health department, and patients were followed by the Children's Tuberculosis Clinic in Houston, TX. Patients were evaluated for changes in symptoms, weight, clinical or radiographic findings and adherence to therapy.
RESULTS: Of the 175 evaluable children (159 pulmonary/thoracic node, 4 pleural, 12 cervical lymph node), 81% of children completed treatment in 6 months. Of the 33 patients who received extended treatment, 3 did so because of physician choice, 17 had an inadequate response to initial therapy, 2 had significant adverse reactions to drugs and 16 had poor adherence to the DOT. Only 37% of patients had complete resolution of disease at the end of treatment, but all continued to improve after therapy was stopped. There was only 1 patient who relapsed after 4 years.
CONCLUSION: This regimen had results comparable with those of 6-month regimens with longer durations of daily therapy. Determining treatment response in pediatric tuberculosis is difficult because of the slow resolution of chest radiograph abnormalities. DOT is an important aspect of treatment but does not solve all problems with treatment adherence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840073     DOI: 10.1097/00006454-200202000-00002

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

Review 1.  Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.

Authors:  Chrysanthi L Skevaki; Dimitrios A Kafetzis
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

Authors:  S M Graham; D J Bell; S Nyirongo; R Hartkoorn; S A Ward; E M Molyneux
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Improving care for urban children with asthma: design and methods of the School-Based Asthma Therapy (SBAT) trial.

Authors:  Jill S Halterman; Belinda Borrelli; Susan Fisher; Peter Szilagyi; Lorrie Yoos
Journal:  J Asthma       Date:  2008-05       Impact factor: 2.515

4.  Prevalence of tuberculosis infection and disease in children referred for tuberculosis medical surveillance in Ontario: a single-cohort study.

Authors:  Catherine Yang; Abdool S Yasseen; Jennifer Stimec; Elizabeth Rea; Valerie Waters; Ray Lam; Shaun K Morris; Ian Kitai
Journal:  CMAJ Open       Date:  2018-08-28

Review 5.  Pharmacokinetics of anti-tuberculosis drugs in children.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; Soumya Swaminathan
Journal:  Indian J Pediatr       Date:  2010-12-17       Impact factor: 1.967

Review 6.  Newer diagnostic modalities for tuberculosis.

Authors:  Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

7.  Identifying the sources of tuberculosis in young children: a multistate investigation.

Authors:  Sumi J Sun; Diane E Bennett; Jennifer Flood; Ann M Loeffler; Steve Kammerer; Barbara A Ellis
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

Review 8.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

9.  Antituberculosis drug-induced hepatotoxicity in children.

Authors:  Peter R Donald
Journal:  Pediatr Rep       Date:  2011-06-16

Review 10.  Recommendations Concerning the First-Line Treatment of Children with Tuberculosis.

Authors:  Nicola Principi; Luisa Galli; Laura Lancella; Marina Tadolini; Giovanni Battista Migliori; Alberto Villani; Susanna Esposito
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.